clofibric acid has been researched along with homocysteine in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (16.67) | 18.2507 |
| 2000's | 10 (83.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Desager, JP; Devuyst, O; Goffin, E; Jamar, F | 1 |
| Abramowicz, D; Broeders, N; Knoop, C | 1 |
| Doolman, R; Gavendo, S; Harats, D; Marko, D; Sela, BA; Shaish, A; Yodfat, O | 1 |
| Aru, GM; Mujumdar, VS; Tummalapalli, CM; Tyagi, SC | 1 |
| Hunt, MJ; Tyagi, SC | 1 |
| Hunt, MJ; Sood, HS; Tyagi, SC | 1 |
| Bozic, M; Fressart, MM; Keber, I; Sebestjen, M; Simcic, S; Stegnar, M; Zegura, B | 1 |
| Písaríková, A; Stanková, B; Tvrzická, E; Vecka, M; Zák, A; Zeman, M | 1 |
| Abalain, JH; Lacut, K; Le Gal, G; Mottier, D; Oger, E | 1 |
| Wierzbicki, AS | 1 |
| Chambers, ST; Elmslie, JL; Fink, JN; George, PM; Lever, M; Richards, AM; Scott, RS; Slow, S | 1 |
| Davidson, MH | 1 |
1 review(s) available for clofibric acid and homocysteine
| Article | Year |
|---|---|
Fibrates in the treatment of cardiovascular risk and atherogenic dyslipidaemia.
Topics: Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Creatinine; Diabetes Mellitus; Dyslipidemias; Homocysteine; Humans; Hypolipidemic Agents; Metabolic Syndrome; Niacin | 2009 |
4 trial(s) available for clofibric acid and homocysteine
| Article | Year |
|---|---|
Homocysteine elevation with fibrates: is it a class effect?
Topics: Adult; Bezafibrate; Clofibric Acid; Dietary Fats; Female; Fibric Acids; Homocysteine; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Triglycerides | 2001 |
Statin and fibrate treatment of combined hyperlipidemia: the effects on some novel risk factors.
Topics: Adult; Arteriosclerosis; Blood Coagulation; Blood Coagulation Factors; Body Weight; C-Reactive Protein; Cholesterol, LDL; Clofibric Acid; Cytokines; Fenofibrate; Homocysteine; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lipids; Male; Middle Aged; Pyridines; Risk Factors | 2004 |
N-3 fatty acid supplementation decreases plasma homocysteine in diabetic dyslipidemia treated with statin-fibrate combination.
Topics: Adult; Albuminuria; Cholesterol Esters; Clofibric Acid; Diabetes Mellitus, Type 1; Dietary Supplements; Fatty Acids; Fatty Acids, Omega-3; Female; Homocysteine; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipoproteins, LDL; Male; Middle Aged; Phosphatidylcholines; Placebos; Stearic Acids; Triglycerides | 2006 |
Fibrates may cause an abnormal urinary betaine loss which is associated with elevations in plasma homocysteine.
Topics: Acute Coronary Syndrome; Aged; Betaine; Clofibric Acid; Cohort Studies; Diabetes Complications; Female; Homocysteine; Humans; Hypolipidemic Agents; Lipids; Male; S-Adenosylmethionine; Stroke | 2009 |
7 other study(ies) available for clofibric acid and homocysteine
| Article | Year |
|---|---|
Implication of fibrate therapy for homocysteine.
Topics: Clofibric Acid; Fenofibrate; Fibric Acids; Glomerular Filtration Rate; Homocysteine; Humans; Hypolipidemic Agents; Kidney Transplantation; Renal Plasma Flow, Effective | 1999 |
Drug treatment of lipid disorders.
Topics: Clofibric Acid; Creatinine; Homocysteine; Humans; Hyperlipidemias; Hypolipidemic Agents; Urea | 1999 |
Mechanism of constrictive vascular remodeling by homocysteine: role of PPAR.
Topics: Antineoplastic Agents; Aorta; Cell Culture Techniques; Clofibric Acid; Collagen; Culture Media, Serum-Free; Disintegrins; Endothelium, Vascular; Fibric Acids; Homocysteine; Humans; Metalloendopeptidases; Muscle, Smooth; Peroxisome Proliferators; Platelet Aggregation Inhibitors; Prostaglandin D2; Receptors, Cytoplasmic and Nuclear; Transcription Factors | 2002 |
Peroxisome proliferators compete and ameliorate Hcy-mediated endocardial endothelial cell activation.
Topics: Animals; Binding, Competitive; Cells, Cultured; Clofibric Acid; Dose-Response Relationship, Drug; Endocardium; Endothelium, Vascular; Fibric Acids; Homocysteine; Intercellular Adhesion Molecule-1; Ligands; Matrix Metalloproteinases; Mice; Myocardium; Prostaglandin D2; Protein Conformation; Receptors, Cytoplasmic and Nuclear; Transcription Factors | 2002 |
Peroxisome proliferator ameliorates endothelial dysfunction in a murine model of hyperhomocysteinemia.
Topics: Animals; Aorta; Blood Pressure; Clofibric Acid; Cystathionine beta-Synthase; Endothelium, Vascular; Enzyme Activation; Fibric Acids; Genotype; Homocysteine; Hyperhomocysteinemia; Matrix Metalloproteinase Inhibitors; Matrix Metalloproteinases; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Peroxisome Proliferators; Phenotype; Proteinuria; Tyrosine | 2003 |
Differential associations between lipid-lowering drugs, statins and fibrates, and venous thromboembolism: role of drug induced homocysteinemia?
Topics: Aged; Aged, 80 and over; Case-Control Studies; Clofibric Acid; Databases, Factual; Female; Homocysteine; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperhomocysteinemia; Hypolipidemic Agents; Male; Middle Aged; Risk Factors; Surveys and Questionnaires; Venous Thromboembolism | 2008 |
A clinical puzzle: fibrates and homocysteine elevation: editorial to: "fibrates may cause an abnormal urinary betaine loss which is associated with elevations in plasma homocysteine" by M. Lever et al.
Topics: Animals; Betaine; Bezafibrate; Clofibric Acid; Dyslipidemias; Folic Acid; Homocysteine; Humans; Hypolipidemic Agents; Metabolic Syndrome | 2009 |